Charts

News

20 Mar, 2024
LOS ANGELES, CA, March 20, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases, today announced Memorial Sloan Kettering Cancer Center as lead clinical site for its NXC-201 relapsed/refractory AL Amyloidosis multi-site clinical trial. “We are looking forward to this important multi-site clinical trial with NXC-201 CAR-T
05 Mar, 2024
Hear from the ~30,000 relapsed or refractory AL Amyloidosis patients in the United States today in their own words Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative Immix Biopharma, Inc. (NASDAQ:IMMX) LOS ANGELES, CA, March 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and autoimmune disease, today announced
21 Feb, 2024
LOS ANGELES, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced its 12-month progress update including shareholder letter. “The past 12 months have seen landmark achievements for Immix Biopharma, cementing our position as a leading cell therapy company in autoimmune disease. We successfully received U.S. FDA investigational new drug clearance for NXC-201. NXC-201 is
08 Feb, 2024
LOS ANGELES, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, announced today the closing of its previously announced underwritten public offering of 5,535,055 shares of its common stock. Each share of common stock was sold at a price to the public of $2.71 per share. The gross proceeds to ImmixBio from this offering are expected to
07 Feb, 2024
European Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 10 years of market exclusivity once authorized in the EUAccess to the EU centralized authorization procedureReduced fees for EU protocol assistance, marketing authorization applications, inspections before authorization, applications for changes to marketing authorizations made after approval, and reduced annual fees U.S. observed prevalence of relapsed/refractory AL Amyloidosis is growing 12% per year according to Staron, et al Blo
06 Feb, 2024
LOS ANGELES, CA, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announced that it has priced an underwritten public offering of 5,535,055 shares of its common stock at an offering price of $2.71 per share of common stock. ImmixBio has granted the underwriters a 30-day option to purchase up to 783,970 additional shares of its com
05 Feb, 2024
LOS ANGELES, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (the “Company”), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares of common stock in the underwritten public offering are to be sold by the Company. The Company also expects to grant the underwriters a 30-day option to purchase additional s
25 Jan, 2024
Shares of Humana Inc. (NYSE: HUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earnings ...
Gainers Onconetix (NASDAQ:ONCO) stock rose 161.5% to $0.39 during Thursday's regular session. The market value of their outstanding ...
24 Jan, 2024
LOS ANGELES, CA, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq:IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced a statement on January 2024, FDA labeling change notifications for approved CAR-T products: “We applaud FDA’s vigilance. Relapsed/refractory AL Amyloidosis remains an unmet medical need with limited treatment options. We believe that Immix Biopharma’s CAR-T
11 Jan, 2024
We can readily understand why investors are attracted to unprofitable companies. For example, Immix Biopharma...
04 Jan, 2024
Dr. Sanchorawala co-authored landmark study of daratumumab (DARZALEX®) in AL Amyloidosis published in The New England Journal of Medicine, 2021 that led to it becoming a first-line standard of careLOS ANGELES, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq:IMMX), announced that effective today, Vaishali Sanchorawala, MD, has joined ImmixBio subsidiary Nexcella Scientific Advisory Board. Dr. Sanchorawala is internationally recognized fo
18 Dec, 2023
Dr. Radic led and authored landmark study demonstrating applicability of CAR-Ts in autoimmune diseases published in Science Translational Medicine, 2019 Dr. Radic is a recognized thought leader in autoimmune CAR-T cell therapy, antibody-mediated disorders and designing CAR-T studies LOS ANGELES, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”), announced that effective today, Marko Radic PhD, has joined ImmixBio subsidiary Nexcella Scientific A
15 Dec, 2023
Gainers Virpax Pharmaceuticals (NASDAQ:VRPX) stock rose 57.8% to $0.38 during Friday's regular session. The market value of their ...
Potential Immix Biopharma, Inc. ( NASDAQ:IMMX ) shareholders may wish to note that the Director, Jason Hsu, recently...
13 Dec, 2023
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money. Today we look at two noteworthy recent insider buys.
11 Dec, 2023
Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023 Immix Biopharma, Inc. (Nasdaq:IMMX) 100% (10/10) overall response rate (ORR) and 70% (7/10) complete response (CR) rate observed in standard of care (Dara-CyBorD) relapsed/refractory AL Amyloidosis patients with median 6 lines of prior therapy in updated Phase 1/2 data as of December 10, 2023Best responder duration
30 Nov, 2023
LOS ANGELES, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announced that it will present and host institutional investor meetings at the 2023 JMP Securities Hematology and Oncology Summit. The JMP Securities Hematology and Oncology Summit Presentation Date: Tuesday, December 5, 2023Presentation Time: 3:30 pm ETLocation: Vi
28 Nov, 2023
Immix Biopharma, Inc. (IMMX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
24 Nov, 2023
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...
22 Nov, 2023
The FDA clears Immix's (IMMX) investigational new drug application for BCMA CAR-T cell therapy, NXC-201, to expand clinical studies in relapsed/refractory AL amyloidosis to the United States. Stock falls.
Virtual Event to be held on November 29, 2023 at 4:15 p.m. ETLOS ANGELES, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq:IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company advancing personalized therapies for oncology and immunology, today announced that it will host a virtual KOL event to discuss its BCMA-Targeted CAR-T cell therapy candidate NXC-201, in development for relapsed/refractory AL amyloidosis (R/R ALA) and relapsed/refractory mul
21 Nov, 2023
NEXICART-2 to expand studies of NXC-201 in relapsed/refractory AL Amyloidosis to U.S. sites based on IND clearance72 patients previously dosed with NXC-201 ex-U.S.First CAR-T program for light-chain (AL) AmyloidosisFavorable tolerability enables expansion into autoimmune indications LOS ANGELES, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq:IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company advancing personalized therapies for oncology and i
06 Nov, 2023
100% overall response rate observed in relapsed/refractory AL Amyloidosis patients with median 6 lines of prior therapyUpdated results will be communicated at the presentation time December 10, 2023 LOS ANGELES, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq:IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announced that additional NXC-201 clinical data in relapsed/refract
23 Oct, 2023
Gainers INVO Bioscience (NASDAQ:INVO) stock moved upwards by 361.1% to $2.49 during Monday's regular session. Trading volume for INVO ...
02 Oct, 2023
Immix Biopharma Inc(NASDAQ: IMMX) announced the presentation of updated data from the ongoing Phase 1b/2 NEXICART-1 study of its ...
25 Sep, 2023
Gainers Femasys (NASDAQ:FEMY) shares moved upwards by 56.8% to $0.52 during Monday's after-market session. This security traded at a ...
21 Sep, 2023
20 Sep, 2023
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. Today we look at two noteworthy recent insider buys.
07 Sep, 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips These best speculative stocks are the ones to buy in the long term for strong returns on your investment portfolio. The post The 3 Best Speculative Stocks to Buy Now: September 2023 appeared first on InvestorPlace. More From InvestorPlace ChatGPT IPO Could Shock the World, Make This Move Before the Announcement Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors
22 Aug, 2023
Gainers Apellis Pharmaceuticals (NASDAQ:APLS) stock rose 33.3% to $41.0 during Tuesday's after-market session. Apellis ...
26 May, 2023
Gainers Elevation Oncology (NASDAQ:ELEV) stock increased by 65.1% to $4.97 during Friday's pre-market session. The market value of ...
22 May, 2023
Gainers Greenhill & Co., Inc. (NYSE: GHL) shares jumped 116.4% to $14.67 after Mizuho announced it would acquire the company ...
Immix Biopharma Inc's(NASDAQ: IMMX) subsidiaryNexcella Incannounced updated AL Amyloidosis clinical data from its ...
Gainers Avrobio (NASDAQ:AVRO) stock increased by 81.9% to $1.41 during Monday's pre-market session. The company's market cap stands at ...
Gainers SeqLL Inc. (NASDAQ: SQL) shares surged 61.1% to $0.54 in pre-market trading after dropping 14% on Friday. SeqLL recently ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about on Monday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Wall Street Titan: Here’s My #1 Stock for 2023 It doesn’t matter if you have $500 or $5 million. Do this now.
03 May, 2023
Immix Biopharma Inc(NASDAQ: IMMX) announced early interim data from IMMINENT-01 Phase 1b/2a trial combining tissue-specific ...
Gainers Aptorum Gr (NASDAQ:APM) shares increased by 199.0% to $8.64 during Wednesday's pre-market session. The company's market cap ...
27 Apr, 2023
Gainers Evelo Biosciences, Inc. (NASDAQ: EVLO) jumped 147.9% to $0.2479. Evelo Biosciences shares dropped 33% on Wednesday after ...
Gainers Evelo Biosciences, Inc. (NASDAQ: EVLO) gained 115.4% to $0.2154 in pre-market trading. Evelo Biosciences shares dropped ...
23 Feb, 2023
Gainers TransMedics Group (NASDAQ:TMDX) stock moved upwards by 16.4% to $75.1 during Thursday's pre-market session. The market value of ...
22 Feb, 2023
Gainers TransMedics Group (NASDAQ:TMDX) stock moved upwards by 10.2% to $71.15 during Wednesday's after-market session. The market ...
Upgrades Maxim Group upgraded the previous rating for TOP Ships Inc (NASDAQ:TOPS) from Hold to Buy. NoneThe stock has a 52-week-high of ...
05 Feb, 2023
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the ...
22 Dec, 2022
Gainers Cue Health (NASDAQ:HLTH) shares rose 13.3% to $2.73 during Thursday's after-market session. The company's market cap stands at ...
14 Dec, 2022
U.S. stocks turned lower toward the end of trading, after the Federal Reserve announced its policy decision. The Dow traded down ...
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ...
U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 100 points on Wednesday The Dow traded up 0.42% to ...
Immix Biopharma Inc(NASDAQ: IMMX) announced it has in-licensed BCMA-targeted next-generation CAR-T therapy NXC-201 (formerly ...
Gainers Vallon Pharmaceuticals (NASDAQ:VLON) stock increased by 137.8% to $0.6 during Wednesday's regular session. Trading volume for ...
27 Oct, 2022
OnThursday, 111 stocks hit new 52-week lows. Interesting Facts About Today's 52-Week Lows: Alphabet ...
26 Oct, 2022
On Wednesday, 53 companies reached new 52-week lows. Intriguing Points From Today's 52-Week Lows: Canon ...
25 Oct, 2022
On Tuesday, 120 companies set new 52-week lows. Areas of Significance In Today's 52-Week Lows: The largest ...
14 Oct, 2022
15:49
FinancialContent
New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 121 stocks hit new 52-week ...
19 Jul, 2022
Gainers Apellis Pharmaceuticals (NASDAQ:APLS) shares rose 24.6% to $55.76 during Tuesday's pre-market session. The ...
07 Jun, 2022
Gainers Kiromic BioPharma, Inc. (NASDAQ: KRBP) gained 70% to $0.4900 after the company entered a sponsored research agreement ...
03 Jun, 2022
09:50
FinancialContent
Gainers NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) shares gained 47.5% to settle at $0.8436 on Thursday. Based on the review of ...
09 May, 2022
07 Oct, 2021

Related Articles